However, not all patients react well to PD-1/PD-L1 immunosuppressants, and the overall rate of response to PD-1/PD-L1 inhibitors in R/M HNSCC patients is less than 20% (43). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.